Yesterday, March 17, 2016, 83 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.79 to $91,240,000.00.

Highlighted Stocks Traded by Insiders:

Macerich (MAC) - FREE Research Report

O Hern Thomas E, who is Senior EVP, Treasurer & CFO at Macerich, sold 5,000 shares at $79.42 on March 17, 2016. Following this transaction, the Senior EVP, Treasurer & CFO owned 46,377 shares meaning that the stake was reduced by 9.73% with the 5,000-share transaction.

The shares most recently traded at $80.81, up $1.39, or 1.72% since the insider transaction. Historical insider transactions for Macerich go as follows:

  • 4-Week # shares sold: 2,760
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 7,760
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 7,760

The average volume for Macerich has been 1.2 million shares per day over the past 30 days. Macerich has a market cap of $11.9 billion and is part of the financial sector and real estate industry. Shares are up 0.05% year-to-date as of the close of trading on Thursday.

The Macerich Company is an independent real estate investment trust. The firm invests in the real estate markets of the United States. The stock currently has a dividend yield of 3.41%. The company has a P/E ratio of 25.9. Currently, there are 3 analysts who rate Macerich a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAC - FREE

TheStreet Quant Ratings rates Macerich as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Macerich Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PNM Resources (PNM) - FREE Research Report

Darnell Ronald N., who is Svp, Public Policy at PNM Resources, sold 113 shares at $33.05 on March 17, 2016. Following this transaction, the Svp, Public Policy owned 26,377 shares meaning that the stake was reduced by 0.43% with the 113-share transaction.

The shares most recently traded at $33.48, up $0.43, or 1.28% since the insider transaction. Historical insider transactions for PNM Resources go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 12,507
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 12,507
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 23,966

The average volume for PNM Resources has been 687,100 shares per day over the past 30 days. PNM Resources has a market cap of $2.7 billion and is part of the utilities sector and utilities industry. Shares are up 10.4% year-to-date as of the close of trading on Thursday.

PNM Resources, Inc., together with its subsidiaries, operates in the energy and energy-related businesses in the United States. The company is primarily involved in the generation, transmission, and distribution of electricity. The stock currently has a dividend yield of 2.63%. The company has a P/E ratio of 167.4. Currently, there are 5 analysts who rate PNM Resources a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PNM - FREE

TheStreet Quant Ratings rates PNM Resources as a buy. Among the primary strengths of the company is its solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full PNM Resources Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cancer Genetics (CGIX) - FREE Research Report

Pappajohn John, who is Director at Cancer Genetics, bought 50,000 shares at $2.64 on March 17, 2016. Following this transaction, the Director owned 1.8 million shares meaning that the stake was boosted by 2.9% with the 50,000-share transaction.

Sharma Panna, who is Chief Executive Officer at Cancer Genetics, bought 1,500 shares at $2.59 on March 17, 2016. Following this transaction, the Chief Executive Officer owned 152,500 shares meaning that the stake was boosted by 0.99% with the 1,500-share transaction.

Welsh Michael J., who is Director at Cancer Genetics, bought 40 shares at $2.42 on March 17, 2016. Following this transaction, the Director owned 5,040 shares meaning that the stake was boosted by 0.8% with the 40-share transaction.

The shares most recently traded at $2.73, up $0.31, or 11.36% since the insider transaction. Historical insider transactions for Cancer Genetics go as follows:

  • 4-Week # shares bought: 101,000
  • 4-Week # shares sold: 5,296
  • 12-Week # shares bought: 101,000
  • 12-Week # shares sold: 5,296
  • 24-Week # shares bought: 206,000
  • 24-Week # shares sold: 5,296

The average volume for Cancer Genetics has been 109,000 shares per day over the past 30 days. Cancer Genetics has a market cap of $35.4 million and is part of the health care sector and health services industry. Shares are down 22.12% year-to-date as of the close of trading on Thursday.

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. Currently, there are 2 analysts who rate Cancer Genetics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CGIX - FREE

TheStreet Quant Ratings rates Cancer Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Cancer Genetics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.